Deals channel feed – Endpoints News

Deals channel feed

Charles River Laboratories snaps up Cognate for a cool $875M, looks to expand cell and gene therapy CDMO foothold

5 years ago

A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal

5 years ago

Nektar, stung by new investor lawsuit over IL-2 drug, secures $150M for Keytruda combo pivotal trial

5 years ago

Novartis partners with the Gates Foundation on one of the Holy Grails in gene therapy: a simple, in vivo approach to curing sickle cell disease

5 years ago

Germany's Rentschler looks to build UK footprint with five-year investment in cell and gene therapies

5 years ago

Quotient, buoyed by Covid-19 work, buys Arcinova in effort to build end-to-end CDMO brand

5 years ago

Bristol Myers takes next big gamble on I/O frontier, pledging nearly $1.4B on Texas firm's tumor toxins

5 years ago

Novartis' Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes

5 years ago

AbbVie taps Jennifer Doudna startup for licensing deal worth up to $300M for 2 'off-the-shelf' CRISPR-edited CAR-Ts

5 years ago

Seqens majority owner looking to sell API maker amid record-high run in healthcare valuations: report

5 years ago

Weighed down by safety concerns of JAK portfolio, Pfizer hatches a deal to go a different direction in rheumatoid arthritis

5 years ago

Jazz vaults into the cannabinoid field with $7.2B GW Pharma buyout

5 years ago

After raising $465M, Kurt von Emster talks about money, biopharma and a new breed of investor: 'The rising tide is pushing everybody into this sector'

5 years ago

GlaxoSmithKline doubles down on CureVac's mRNA tech, bets $180M on the hunt for next-gen vaccine

5 years ago

WuXi STA snaps up Bristol Myers Squibb facility, plants feet in European CDMO marketplace

5 years ago

Vertex is poised for a shopping spree. But it’s still unclear just what might go into their basket — and at least one analyst is getting impatient

5 years ago

The packed PD-(L)1 game just got another player — a low-profile biosimilars company looking to branch out with a $150M cash pact

5 years ago

Horizon nabs another rare disease pipeline for the portfolio in $3B buyout. And AstraZeneca — a future rival — is getting about $780M of that

5 years ago

Biotech partner drops GlaxoSmithKline’s adjuvant as it moves Covid-19 vaccine into PhII/III, citing ‘manufacturing considerations’

5 years ago

In pursuit of an HIV cure, Gilead jumps into a T cell-driving vaccine program with a $785M deal that triggers PhI

5 years ago

Lilly attempts to revive an old idea for tackling pain, licensing PhI program from Japan’s Asahi Kasei Pharma

5 years ago

Top gene therapy deals, M&A pacts in 2020 highlight another big year in one of the hottest fields in biopharma

5 years ago

Dean Li kicks off Merck's post-Roger Perlmutter era by teaming with Artiva and its off-the-shelf CAR-NK tech

5 years ago

Psychedelic biotech ATAI hopes to expand portfolio through research partnership with Mass General

5 years ago

First page Previous page 80 81 828384 85 86 Next page Last page